IP Library Granted Patent US 6,869,605
Granted Patent B2
US 6,869,605 · App. 09/911,777 · Granted Mar 22, 2005

BAFF, inhibitors thereof and their use in the modulation of B-cell response

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,869,605
App. No.
09/911,777
Granted
Mar 22, 2005
Kind
B2
Abstract

The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists.

Claims (14)

1. A method of inhibiting B-cell growth in an animal comprising the step of administering a therapeutically effective amount of an anti-BAFF antibody that binds human BAFF (SEQ ID NO:1), wherein B-cell growth in the animal is inhibited.

2. A method of inhibiting immunoglobulin production in an animal comprising the step of administering a therapeutically effective amount of an anti-BAFF antibody that binds human BAFF (SEQ ID NO:1), wherein immunoglobulin production in the animal is inhibited.

3. A method of co-inhibiting B-cell growth and immunoglobulin production in an animal comprising the step of administering a therapeutically effective amount of an anti-BAFF antibody that binds human BAFF (SEQ ID NO:1), wherein B-cell growth and immunoglobulin production in the animal are inhibited.

4. A method of inhibiting B-cell growth and maturation in an animal comprising the step of administering a therapeutically effective amount of an anti-BAFF antibody that binds human BAFF (SEQ ID NO:1), wherein B-cell growth and maturation in the animal are inhibited.

5. A method of inhibiting B-cell growth in an animal comprising the step of administering a therapeutically effective amount of an anti-BAFF antibody that binds murine BAFF (SEQ ID NO:2), wherein B-cell growth in the animal is inhibited.

6. A method of inhibiting immunoglobulin production in an animal comprising the step of administering a therapeutically effective amount of an anti-BAFF antibody that binds murine BAFF (SEQ ID NO:2), wherein immunoglobulin production in the animal is inhibited.

7. A method of co-inhibiting B-cell growth and immunoglobulin production in an animal comprising the step of administering a therapeutically effective amount of an anti-BAFF antibody that binds murine BAFF (SEQ ID NO:2), wherein B-cell growth and immunoglobulin production in the animal are inhibited.

8. A method of inhibiting B-cell growth and maturation in an animal comprising the step of administering a therapeutically effective amount of an anti-BAFF antibody that binds murine BAFF (SEQ ID NO:2); wherein B-cell growth and maturation in the animal are inhibited.

9. The method according to any one of claims 1 - 8 , wherein the anti-BAFF antibody is a monoclonal antibody.

10. The methods of claim 9 , wherein the antibody is recombinantly produced.

11. The method as in claim 9 , wherein the antibody is a chimeric antibody.

12. The method as in claim 9 , wherein the antibody is a humanized antibody.

13. The method as in claim 9 , wherein the antibody comprises human constant domains.

14. The method as in claim 9 , wherein the antibody is a F(ab') 2 fragment.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2004
From: BROWNING, JEFFREY; AMBROSE, CHRISTINE; MACKAY, FABIENNE
To: BIOGEN IDEC MA INC.
Reel/Frame 014465/0793 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2004
From: TSCHOPP, JURG; SCHNEIDER, PASCAL; APOXIS S.A.
To: BIOGEN IDEC MA INC.
Reel/Frame 014375/0280 →